Adverse drug reactions to nonnucleoside reverse transcriptase inhibitor-based antiretroviral regimen: A 24-week prospective study

Journal of the International Association of Physicians in AIDS Care

Volumn 8, Issue 5, 2009, Pages 318-322

  Jena, Anupam ^a   Sachdeva, Ravinder K ^a   Sharma, Aman ^a   Wanchu, Ajay ^a  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

adverse drug reaction; AIDS; anti retroviral therapy; HIV; nonnucleoside reverse transcriptase inhibitor

Indexed keywords

BENZOXAZINE DERIVATIVE; EFAVIRENZ; LAMIVUDINE; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; ZIDOVUDINE;

ABDOMINAL PAIN; ADULT; AGED; APPETITE; ARTICLE; CD4 LYMPHOCYTE COUNT; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; DIZZINESS; DREAM; DRUG COMBINATION; DRUG EFFECT; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPESTHESIA; INSOMNIA; MALE; MIDDLE AGED; NAUSEA; PROSPECTIVE STUDY; RASH; SLEEP STAGE; TOXIC HEPATITIS; VOMITING;

ABDOMINAL PAIN; ADULT; AGED; APPETITE; BENZOXAZINES; CD4 LYMPHOCYTE COUNT; DIZZINESS; DREAMS; DRUG THERAPY, COMBINATION; DRUG-INDUCED LIVER INJURY; EXANTHEMA; FEMALE; HIV INFECTIONS; HUMANS; HYPESTHESIA; LAMIVUDINE; MALE; MIDDLE AGED; NAUSEA; NEVIRAPINE; PROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; SLEEP INITIATION AND MAINTENANCE DISORDERS; SLEEP STAGES; STAVUDINE; VOMITING; ZIDOVUDINE;

EID: 75349090739     PISSN: 15451097     EISSN: 15570886     Source Type: Journal    
DOI: 10.1177/1545109709343967     Document Type: Article

References (11)

1. Pau AK Clinical management of drug interaction with antiretroviral agents. Curr Opin HIV AIDS. 2008 ; 3 (3). 319-324. (Pubitemid 351521017)
2. O'Brien ME, Clark RA, Besch CL, Myers L., Kissinger P. Patterns and correlates of discontinuation of the initial HAART regimen in an urban outpatient cohort. J Acquir Immune Defic Syndr. 2003 ; 34 (4). 407-414. (Pubitemid 37444469)
3. Moh R., Danel C., Messou E., et al. Incidence and determinants of mortality and morbidity following early antiretroviral therapy initiation in HIV-infected adults in West Africa. AIDS. 2007 ; 21 (18). 2483-2491. (Pubitemid 350145180)
4. Hernando K., Miro Jose M., Beatriz M., et al., and the Grupo Estudio Syndrome Immunodeficiencies Adquirida 26/02 Study Group. Failure of cetrizine to prevent nevirapine-associated rash: a double-blind placebo-controlled trial for the GESIDA 26/01 Study. J Acquir Immune Defic Syndr. 2004 ; 37 (2). 1276-1281.
5. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. 2008; 1-128. http://www.aidsinfo.nih.gov/ ContentFiles/ AdultandAdolescentGL. pdf. Accessed January 29, 2008.
6. Knobel H., Miró JM, Domingo P., et al., and the GESIDA 09/99 Study Group. Failure of a short-term prednisone regimen to prevent nevirapine-associated rash: a double-blind placebo-controlled trial: the GESIDA 09/99 study. J Acquir Immune Defic Syndr. 2001 ; 28 (1). 14-18. (Pubitemid 33104522)
7. AIDS Clinical Trial Group. Table for Grading Adult Adverse Experiences. Rockville, MD: Division of AIDS, National Institute of Allergy and Infectious Diseases ; 1996.
8. Kumarasamy N., Venkatesh KK, Cecelia AJ, et al. Spectrum of adverse events after generic HAART in southern Indian HIV-infected patients. Aids Patient Care STDS. 2008 ; 22 (4). 337-344. (Pubitemid 351562965)
9. Wanchu A., Pareek S., Bambery P., et al. Adverse drug reactions to generic antiretroviral medications in resource constrained settings: implication for scaling up therapy [abstract 562]. Paper presented at: 13th Conference on Retroviruses and Opportunistic Infections ; 2006 ; Denver, CO.
10. Bersoff-Matcha SJ, Miller WC, Aberg JA, et al. Sex differences in nevirapine rash. Clin Infect Dis. 2001 ; 32 (1). 124-129. (Pubitemid 32150957)
11. Antinori A., Baldini F., Girardi E., et al. Female sex and the use of anti-allergic agents increase the risk of developing cutaneous rash associated with nevirapine therapy. AIDS. 2001 ; 15 (12). 1579-1581. (Pubitemid 32744607)